SET domain containing 6, protein lysine methyltransferaseGenealiases: []
Q-omics provides the consensus-scored SETD6 profile across patient tissues and cancer cell-line models. SETD6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SETD6 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SETD6 RNA expression shows 20,296 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, COAD, and UVM as cancer lineages where SETD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETD6 survival associations across molecular data types. SETD6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETD6 RNA expression–survival associations across cancer types. High SETD6 expression shows unfavorable associations in LGG, CESC, KIRC, LIHC and BLCA, but favorable associations in SCLC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SETD6 RNA expression.
This table summarizes SETD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SETD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETD6 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, LIHC, LUAD and LUSC. The COAD box plot shows higher SETD6 RNA expression in tumor versus normal tissue (log2 FC = +1.210, t-test p < 0.001).
This table shows molecular features associated with SETD6 in patient tissues and cancer cell lines. In patient samples, SETD6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SETD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
